Sign up for our free daily newsletter
Get the latest news and some fun stuff
in your inbox every day
Get the latest news and some fun stuff
in your inbox every day
Aspen announced that the GSK sale had happened yesterday, I am more interested in who the buyer was. The announcement was pretty brief, the important line being: " .. its beneficial interests in Aspen Holdings now amounts to 12.4% of the total number of shares in issue." There you go, portion sold, they have taken all of their money off the table and now are still a significant shareholder. An old friend of the newsletter (he is not old, the newsletter is getting there) had this contribution:
"It is noteworthy how Big Pharma is selling assets. First Pfizer with Zoetis, Merck looking to unbundle/sell its animal health division and now GlaxoSmithKline selling down one third of its Aspen stake with probably more to follow. One can hypothesize any number of reasons, but GSK is probably the most puzzling. One would have thought that they would rather try & take Aspen out to give them unrivalled access to Aspen's extensive distribution business, rather like Kraft Foods (now Mondelez) buying Cadbury's more for its worldwide distribution facilities rather than its brands. Could Big Pharma be after funds as each strives to discover and deliver a blockbuster cancer drug that they can then sell at $100,000 per treatment course per patient, as is now beginning to happen? With aging demographics and an accelerating incidence of cancer, it might explain these moves."